Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger
PR Newswire•17/11/2026•08:05 ET
0
Key Highlights
- ➤Merger with Eos SENOLYTIX expected to close by end of 2026
- ➤Pulmatrix obtained SEC effectiveness and stockholder approval for the proposed merger
- ➤Third-quarter net loss attributable to common stockholders reached $1.234 million
- ➤Cash and equivalents fell to $1.4 million from $4.1 million at year-end 2025
- ➤All clinical development remains on hold while Pulmatrix seeks asset monetization
Expert Statements
Peter Ludlum, Interim Chief Executive Officer of Pulmatrix
“Our focus in the third quarter and beyond has been to advance steps towards completing the proposed merger with Eos SENOLYTIX, a privately held biotechnology company developing novel gerotherapeutic peptides targeting mitochondrial dysfunction in aging-related diseases using the MitoXcel™ platform.”
Peter Ludlum, Interim Chief Executive Officer of Pulmatrix
“To that end, we have obtained SEC effectiveness on our registration statement on Form S-4 in relation to the merger as well as approval from our stockholders on the proposed merger.”
Peter Ludlum, Interim Chief Executive Officer of Pulmatrix
“We anticipate closing the proposed merger by the end of the year.”
Pulmatrix Announces Third Quarter 2026 Financial Results and Progress on Merger PR Newswire
Merger with Eos SENOLYTIX expected to close by end of the year
Get started
Create a free account to read the full story.
